Revvity Q3 revenue beats estimates, raises FY guidance
RVTY•Revvity’s third-quarter revenue rose 7% year over year to $729 million, beating the $698.15 million estimate, while adjusted EPS of $1.37 topped the $1.30 estimate. The company raised its 2026 outlook, forecasting about $2.86 billion in pro forma revenue and adjusted EPS of $5.40-$5.45.
1. Quarterly results
Revvity reported third-quarter revenue of $729 million, up 7% year over year and above analysts’ $698.15 million estimate. Adjusted EPS was $1.37, compared with the $1.30 estimate.
2. 2026 outlook
The company forecasts 2026 pro forma revenue of about $2.86 billion, pro forma organic revenue growth of about 5%, and adjusted EPS of $5.40-$5.45.
3. Segment performance
Life Sciences pro forma revenue increased 11%, while Diagnostics pro forma revenue rose 4%. Revvity said adjusted operating profit margins increased in both segments, and its CEO cited improving end-market conditions.
